Bliss GVS Pharma (506197) Q4 24/25 earnings summary

Executive summary

• Audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, were approved, with an unmodified audit opinion issued for both.

• Final dividend of ₹0.50 per equity share recommended, subject to shareholder approval at the 40th AGM scheduled for July 31, 2025.

• Board approved issuance of up to 12,10,000 sweat equity shares to key management for non-cash consideration, pending shareholder and regulatory approvals.

• Sale of 51% stake in step-down subsidiary Greenlife Bliss Healthcare Ltd. approved, with transaction expected to complete by September 30, 2025.

Financial highlights

• Consolidated revenue for FY25 was ₹84,621.97 lakh, up from ₹79,898.23 lakh in FY24.

• Consolidated net profit for FY25 was ₹8,790.97 lakh, compared to ₹8,612.64 lakh in FY24.

• Standalone revenue for FY25 was ₹70,342.11 lakh, up from ₹63,896.02 lakh in FY24.

• Standalone net profit for FY25 was ₹6,841.15 lakh, up from ₹5,049.13 lakh in FY24.

• Earnings per share (consolidated, basic) for FY25 was ₹8.02, compared to ₹7.23 in FY24.

Outlook and guidance

• Sale of subsidiary and asset classified as held for sale expected to complete by September 30, 2025.

• Transaction for sweat equity shares and secretarial auditor appointment subject to shareholder approval at the upcoming AGM.